- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03132090
Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI
April 24, 2017 updated by: Prof. Dr. Nina Schwenzer, University Hospital Tuebingen
Early Response Monitoring of Systemic Therapies in Patients With Advanced Melanoma by Simultaneous Positron-emission-tomography (PET)/Magnetic Resonance Imaging (MRI)
Therapeutic agents used in malignant melanoma treatment such as BRAF/MEK inhibitors and anti-CTLA-4/Anti-PD-1 antibodies go along with harmful side effects in a considerable proportion of patients and treatment costs may cause relevant medical expenditures per month.
Currently, therapy response assessment in melanoma patients is performed using RECIST criteria which are based on changes in tumour size.
PET/CT combines morphological and metabolic information.
Thus, the so-called PERCIST-criteria were introduced integrating change in size and glucose utilization for response assessment in solid tumors.
Due to the different mechanism of action these new agents introduce different response patterns increase in tumor size due to inflammation for antibody therapies).
In conventional chemotherapies, re-staging is usually performed 3 months after treatment initiation which is the result of empirical investigations.
Moreover, it has recently been shown, that response to new targeted therapies can be detected much earlier using PET or functional MR techniques.
This forms the rationale for the monitoring of melanoma patients using a combined PET/MR technique after only 2 weeks of therapy initiation.
Especially for patients in stage IV with a medium survival time of 12 months, a 2.5 months earlier re-staging and therapy adjustment would have significant consequences for the individual clinical course.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
106
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nina Schwenzer, MD
- Phone Number: +49 7071 29-87720
- Email: nina.schwenzer@uni-tuebingen.de
Study Locations
-
-
-
Tuebingen, Germany, 72076
- Recruiting
- Dept. of Radiology, University of Tuebingen
-
Contact:
- Christina Pfannenberg, MD
- Phone Number: +49 7071 2982756
- Email: christina.pfannenberg@med.uni-tuebingen.de
-
Contact:
- Brigitte Gueckel
- Phone Number: +49 7071 2981212
- Email: brigitte.gueckel@med.uni-tuebingen.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patient with diagnosed unresectable malignant melanoma stage IV
- age: ≥18 years
- planned systemic therapy with either new therapies (BRAF/MEK inhibitors, Anti-CTLA-4/Anti-PD-1 antibodies) or conventional chemotherapeutics (CTx)
- clinically indicated routine PET/CT (baseline t0) demonstrating at least one measurable lesion
- PET/CT for baseline-staging and therapy monitoring (clinical indication required)
- informed consent
Exclusion Criteria:
- contraindications for MR-imaging (metal implants, claustrophobia, etc.)
- contraindications for gadolinium-based contrast agent
- acute infections or other acute diseases
- pregnant or breast-feeding women
- disability for informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early therapy response assessment
Time Frame: Baseline t0 (1st imaging / start of therapy), early therapy response (study visit) t1 (2 weeks after therapy start), regular therapy response (routine visit) t2 (3 month after therapy start)
|
Early therapy response assessment by multiparametric hybrid imaging (PET/MRI) two weeks (early time point - study visit) and three months (regular staging) after therapy initiation with regard to optimizing patient management (please note: no therapy change intended based on the imaging at early time point (study visit t1)).
Early study imaging data and later regular imaging data have to be compared.
|
Baseline t0 (1st imaging / start of therapy), early therapy response (study visit) t1 (2 weeks after therapy start), regular therapy response (routine visit) t2 (3 month after therapy start)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
prognostic capacity of morphological and functional MRI measures
Time Frame: 3 month
|
testing the prognostic capacity of morphological and functional MRI measures (diffusion, perfusion) for predicting the concordance of therapy response results two weeks and three months after treatment initiation
|
3 month
|
prognostic value of PET/MRI-specific response
Time Frame: 18 month
|
validation of the significance and prognostic value of the defined PET/MRI-specific response evaluation criteria by correlation with TTP
|
18 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 29, 2014
Primary Completion (Anticipated)
January 1, 2018
Study Completion (Anticipated)
June 1, 2018
Study Registration Dates
First Submitted
March 7, 2017
First Submitted That Met QC Criteria
April 24, 2017
First Posted (Actual)
April 27, 2017
Study Record Updates
Last Update Posted (Actual)
April 27, 2017
Last Update Submitted That Met QC Criteria
April 24, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GK-MR/PET Tü-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma Stage IV
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
Bart NeynsVrije Universiteit BrusselCompletedMalignant Melanoma Stage III | Malignant Melanoma Stage IVBelgium
-
Baylor Research InstituteNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Melanoma Stage III | Malignant Melanoma Stage IVUnited States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
Medical University of GrazBristol-Myers SquibbTerminatedMalignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota TransplantationAustria
-
Universitair Ziekenhuis BrusselRIZIVCompletedMalignant Melanoma Stage III | Malignant Melanoma Stage IVBelgium
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant MelanomaUnited States
-
OncoHost Ltd.RecruitingStage IV Non-small Cell Lung Cancer | Stage III Malignant Melanoma | Stage IV Small Cell Lung Cancer | Stage IV Malignant MelanomaUnited States, Israel, United Kingdom, Germany, Spain
-
Scancell LtdRecruitingMelanoma (Skin) | Malignant Melanoma | Melanoma Stage IV | Melanoma Stage IIIUnited Kingdom
Clinical Trials on PET/MR (Biograph mMR)
-
Cedars-Sinai Medical CenterRecruitingCoronary Artery Disease | CancerUnited States
-
Seoul National University HospitalUnknownProstate Cancer Recurrent | Stage II Prostate Carcinoma | Stage III Prostate CarcinomaKorea, Republic of
-
Assuta Medical CenterHadassah Medical OrganizationUnknownAlzheimer Disease | Mild Cognitive Impairment
-
NYU Langone HealthCompletedProstate Cancer | Bladder CancerUnited States
-
Massachusetts General HospitalCompleted
-
NYU Langone HealthTerminatedMultiple Sclerosis | Cognition DisordersUnited States
-
NYU Langone HealthCompleted
-
NYU Langone HealthSociety of Abdominal RadiologyCompletedBladder CancerUnited States
-
Universitair Ziekenhuis BrusselRecruitingCancer | Carotid Stenosis | Non Hodgkin Lymphoma | Sarcoidosis | Cardiac Sarcoidosis | Hodgkin Lymphoma, Adult | Atherosclerosis of Artery | HLH | Solid Malignancy Located in the Head and NeckBelgium
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States